Navigation Links
Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
Date:5/28/2008

SOUTH SAN FRANCISCO, Calif., May 28 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) will present data from ongoing clinical trials of voreloxin (formerly SNS-595) at two major upcoming oncology conferences.

Updated interim data from Sunesis' ongoing Phase 2 clinical trial of voreloxin in platinum-resistant ovarian cancer patients will be presented during the 44th American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30 - June 3, 2008 in Chicago, Illinois.

Updated results and a comparative safety and response analysis in older patients (>/= 60 years old) and younger patients (< 60 years old) from the company's Phase 1 clinical trial of voreloxin in relapsed or refractory acute leukemia patients will be presented at the 13th Congress of the European Hematology Association (EHA) being held June 12 - 15, 2008 in Copenhagen, Denmark. The presentation will also include preliminary data from the company's Phase 1b trial of voreloxin combined with cytarabine in relapsed/refractory acute myeloid leukemia (AML) patients. In addition, data from the company's ongoing Phase 1 clinical trial of SNS-032 in patients with chronic lymphocytic leukemia and multiple myeloma will be presented at EHA.

44th ASCO Annual Meeting

o A PHASE 2 TRIAL OF SNS-595 IN WOMEN WITH PLATINUM RESISTANT EPITHELIAL

OVARIAN CANCER

Abstract #5582

General poster session Gynecologic Cancer: Ovarian Cancer

Saturday, May 31, 2008, 8:00 a.m. - 12:00 p.m. CST, S Hall A1

13th Congress of the European Hematology Association

o SAFETY AND EFFICACY EXPERIENCE OF SNS-595 IN RELAPSED/REFRACTORY ACUTE

LEUKEMIA PATIENTS >/= 60 YEARS OLD COMPARED TO < 6
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015 Numotion,s Board of ... announced that Tamas Feitel has joined the ... Numotion after a highly successful 18 year career at ... driving strategy, profitability, and productivity to result in significant ... position was Chief Financial Officer for GE Healthcare Global ...
(Date:7/2/2015)... DUBLIN , June 25, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/8mfjxh/2015_new ) has announced the addition of ... Chemistry and Immunodiagnostics: Global Challenges, Emerging Technologies, ... 2015 New Frontiers in Clinical ... Competitive Landscape is a new seven-country strategic ...
(Date:7/2/2015)... 2015  AbbVie (NYSE: ABBV ) will announce ... 2015, before the market opens. AbbVie will ... at 8 a.m. Central time (9 a.m. Eastern). It ... www.abbvieinvestor.com . An archived edition of the call ... About AbbVie AbbVie is a global, ...
Breaking Medicine Technology:Numotion Names Tamas Feitel Chief Financial Officer 2New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2
... Company (NYSE:  KVa/KVb) today announced the establishment of a ... appointment of Mark Hartman as its President. ... the Company, stated, "Mark brings recognized depth and breadth ... are excited to have Mark join our organization and ...
... launch of MEDI PORT, C PORT Solutions is ... communication and collaboration with patient data, medical applications, and ... or treat a patient with the highest level of ... MEDI PORT is a powerful mobile computing platform ...
Cached Medicine Technology:K-V Pharmaceutical Company Announces Establishment of New Generic Marketing Subsidiary and Senior Executive Appointment 2K-V Pharmaceutical Company Announces Establishment of New Generic Marketing Subsidiary and Senior Executive Appointment 3K-V Pharmaceutical Company Announces Establishment of New Generic Marketing Subsidiary and Senior Executive Appointment 4K-V Pharmaceutical Company Announces Establishment of New Generic Marketing Subsidiary and Senior Executive Appointment 5K-V Pharmaceutical Company Announces Establishment of New Generic Marketing Subsidiary and Senior Executive Appointment 6K-V Pharmaceutical Company Announces Establishment of New Generic Marketing Subsidiary and Senior Executive Appointment 7K-V Pharmaceutical Company Announces Establishment of New Generic Marketing Subsidiary and Senior Executive Appointment 8C PORT Solutions Launches MEDI PORT to Bring Powerful New Telemedicine Solutions to the Hospital Bedside 2C PORT Solutions Launches MEDI PORT to Bring Powerful New Telemedicine Solutions to the Hospital Bedside 3
(Date:7/3/2015)... ... 03, 2015 , ... Scientists at several top US cancer centers believe they ... exposure. Click here to read the complete story , just posted on the ... Sinai Medical Center, and New York University exposed mice with a mutation on the ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... Smoothies are ... is a good blender and easily accessible, quality ingredients. Aurora Natural is proud to ... for an added boost of fiber, protein, antioxidants, vitamins and minerals! , Aurora is ...
(Date:7/3/2015)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... biblical truth and expose popular lies regarding proper relationships according to the bible. ... goes into the core of the subject by explaining why certain types of sexual ...
(Date:7/2/2015)... ... , ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its ... in the Lone Star State. The premium frozen yogurt chain was listed as #22 ... which opened July 1 at Duke’s Travel Plaza, is located at:, 30176 Hwy 64, ...
(Date:7/2/2015)... ... July 02, 2015 , ... With summer in full swing, Americans are flocking to Canada’s many ... top spots for fishing in the world, and it’s easy to understand why. From the ... great fish. , Recreational fishing is a huge industry, and Americans make up the ...
Breaking Medicine News(10 mins):Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2Health News:sweetFrog Expands Texas Footprint with Location in Canton 2
... than 1lb 6oz. He was so weak that he needed life ... he lived and grew stronger. //Even his mother Donna Morgan who ... be given blood transfusions to recover. ,Now the mother ... helped them, they are launching a campaign to fill the worryingly ...
... poultry worker in West Sumatra is infected with the ... in Indonesia to 33// , a health ministry official ... WHO Tuesday morning," said Hariyadi Wibisono, director general of ... poultry worker, identified as Achyan, was being treated in ...
... Ashok Bhatt has confirmed the absence of bird-flu cases in ... yielded negative results. ,Kadar Murghiwala, a poultry dealer ... died. Suspecting a possible bird-flu infection following complaints of fever, ... an isolation ward. The symptoms of bird-flu as listed by ...
... According to a study, patients with breast cancer, who are ... likely to die of the disease// than those who are ... H. Kroenke, women diagnosed with breast cancer should know that ... survive the disease, reported news portal All Headline News. ...
... rates in the state, Madhya Pradesh legislators seems to be ... a voluntary group//. ,The state, one of the largest ... per 1,000 childbirths while the maternal mortality rate stands at ... having the second highest rate of infant and maternal mortality ...
... published in the April issue of IJCP, the International ... cent of cases of invasive// pneumococcal diseases (IPD) like ... countries still only vaccinate selected at-risk groups against IPD. ... universal vaccination of infants and young children reduces their ...
Cached Medicine News:Health News:Promotion of Pneumococcal Vaccine Slow in Europe 2Health News:Promotion of Pneumococcal Vaccine Slow in Europe 3
Versatility of the DFS Standard Fixator provides unsurpassed below-the-ring correction of angular, rotational and translational deformities. Length discrepancy can be precisely corrected in 1/4mm inc...
A major advancement in the management of Pelvic Fracture Care, permitting rapid stabilization and surgical access....
The PreFix™ temporary fixator prepares you for any situation that requires rapid stabilization of complex fractures....
The large External Fixator consists of rods, clamps, and pins. It has multiple external fixation frames, independent pin placement, and MR safe clamps. The modular frame construction permits fracture...
Medicine Products: